Major Events - Black Sesame Intelligence (02533) plans to acquire and increase its stake to 60% in Zhuhai Yizhi Electronic Technology, aiming to establish a full-scenario ecosystem for AI chips [1] - China Biopharmaceutical (01177) has completed the enrollment of the first patient in the Phase III clinical trial of its self-developed TDI01 "ROCK2 inhibitor" for the treatment of idiopathic pulmonary fibrosis [1] - Cao Cao Travel (02643) sees a positive outlook and its controlling shareholder voluntarily extends the lock-up commitment [1] - Laike Pharmaceutical-B (02105) has completed the first dosing of the Phase I single-dose escalation study for LAE103 [1] - VALA (02051) has launched its new model, Vala Home, and is collaborating with Ruichi Automobile to enhance production capacity and delivery systems [1] Operating Performance - BYD Company (01211) expects to achieve approximately 4.6024 million units in new energy vehicle sales for 2025, representing a year-on-year increase of 7.73% [1] - Geely Automobile (00175) reported total vehicle sales of 236,800 units in December, a year-on-year increase of approximately 13% [1] - NIO Inc. (09866) delivered 48,100 vehicles in December, setting a new monthly record with a year-on-year increase of 54.6% [1] - Great Wall Motors (02333) anticipates sales of approximately 1.3237 million units for 2025, reflecting a year-on-year growth of 7.33% [1] - Xpeng Motors (09868) achieved a total delivery of 429,400 vehicles for the entire year of 2025, marking a year-on-year increase of 126% [1] - China Power (02380) reported a total consolidated electricity sales volume of 10.0997 million megawatt-hours in November, an increase of 15.38% year-on-year [1] - Li Auto (02015) delivered 44,200 new vehicles in December, a year-on-year decrease of 24.44% [1]

Core Viewpoint - Standardized management of hematopoietic stem cell transplantation is crucial for improving long-term quality of life for patients [1][2] Group 1: cGVHD Management - Chronic graft-versus-host disease (cGVHD) affects 30% to 70% of patients who undergo allogeneic hematopoietic stem cell transplantation, impacting multiple organs and tissues [1] - cGVHD is a leading cause of mortality among long-term complications of hematopoietic stem cell transplantation, necessitating comprehensive care [1] - More than half of cGVHD patients require second-line or later treatments after first-line standard therapy, with new targeted drugs emerging in recent years [1] Group 2: Healthcare Innovations - The first follow-up outpatient clinic for hematopoietic stem cell transplantation has been established in Guangdong Province, focusing on cGVHD management through a comprehensive early screening, diagnosis, and treatment system [2] - This new model aims to provide continuous and standardized medical support for patients post-transplant, potentially setting a precedent for future management of transplantation [2]